会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • C형 간염 바이러스의 마크로사이클릭 억제제
    • HEPATITIS C病毒的大肠抑制剂
    • KR1020080039422A
    • 2008-05-07
    • KR1020087003697
    • 2006-07-28
    • 얀센 알 앤드 디 아일랜드메디비르 아베
    • 드콕크헤르만아우구스티누스심멘케네스알란욘손칼에릭다니엘아에사알바레즈수산나클라손비요른올로프닐손칼마그누스로젠퀴스트아사아니카크리스티나사무엘손벤그트베르틸발베르그한스크리스티안
    • C07D401/12C07D403/12C07D413/12A61K31/538
    • C07D403/12C07D401/12C07D413/12C07D487/04
    • Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is-OR6,-NH-SO2R7; R 2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 taken together with the nitrogen atom to which they are attached form a bicyclic ring system selected from formula (II) wherein said ring system may optionally be substituted with 1-3 substituents; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6 alkyl; or C1-6alkyl optionally substituted with C3-7 cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7 cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each of which may be optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from N, O or S, and being optionally substituted with 1-3 substituents pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
    • 式(I)的HCV复制抑制剂及其N-氧化物,盐或立体异构体,其中每个虚线表示任选的双键; X为N,CH,X为双键,C为C; R1是-OR6,-NH-SO2R7; R 2是氢,并且其中X是C或CH,R 2也可以是C 1-6烷基; R 3是氢,C 1-6烷基,C 1-6烷氧基C 1-6烷基或C 3-7环烷基; n为3,4,5或6; R4和R5与它们所连接的氮原子一起形成选自式(II)的双环体系,其中所述环系可以任选被1-3个取代基取代; R6是氢; 芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基,芳基或与Het取代的C 1-6烷基; R7是芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基,芳基或与Het取代的C 1-6烷基; 芳基是苯基或萘基,每个可以任选被1-3个取代基取代; Het是含有1至4个独立地选自N,O或S的杂原子的5或6元饱和的,部分不饱和的或完全不饱和的杂环,并且任选被1-3个取代基取代,含有化合物(I)的药物组合物和 制备化合物(I)。 还提供了式(I)的HCV抑制剂与利托那韦的生物可利用组合。
    • 6. 发明公开
    • C형 간염 바이러스의 마크로사이클릭 억제제
    • HEPATITIS C病毒的大肠抑制剂
    • KR1020080039938A
    • 2008-05-07
    • KR1020087004541
    • 2006-07-28
    • 얀센 알 앤드 디 아일랜드메디비르 아베
    • 라보이쏜피에르쟌-마리에베르나드드콕크헤르만아우구스티누스심멘케네스알란욘손칼에릭다니엘닐손칼마그누스로젠퀴스트아사아니카크리스티나사무엘손벤그트베르틸안토노브드미트리살바도르오덴로우데스아에사알바레즈수산나클라손비요른올로프
    • C07D401/12C07D403/12A61K31/4523A61P31/14
    • C07D401/12C07D225/04C07D245/04C07D403/12C07D413/12C07D417/12C07D487/04
    • Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is-OR6,-NH-SO 2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R 5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy-carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R 6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R 7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1-4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1-3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
    • 式(I)的HCV复制抑制剂及其N-氧化物,盐或立体异构体,其中每个虚线(由 - 表示)表示任选的双键; X为N,CH,X为双键,C为C; R1是-OR6,-NH-SO2R7; R2是氢,并且其中X是C或CH,R2也可以是C1-6烷基; R 3是氢,C 1-6烷基,C 1-6烷氧基C 1-6烷基或C 3-7环烷基; n为3,4,5或6; R 4和R 5彼此独立地是氢,卤素,羟基,硝基,氰基,羧基,C 1-6烷基,C 1-6烷氧基,C 1-6烷氧基C 1-6烷基,C 1-6烷基羰基,C 1-6烷氧基羰基,氨基,叠氮基,巯基 ,C 1-6烷硫基,多卤代C 1-6烷基,芳基或Het; W是芳基或Het; R 6是氢; 芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基,芳基或与Het取代的C 1-6烷基; R 7是芳基; HET; 任选被C 1-6烷基取代的C 3-7环烷基; 或任选被C 3-7环烷基,芳基或与Het取代的C 1-6烷基; 芳基是苯基或萘基,各自任选被1-3个取代基取代; Het是含有1-4个杂原子的5或6元饱和的,部分不饱和的或完全不饱和的杂环,各自独立地选自N,O或S,并且任选被1-3个取代基取代; 含有化合物(I)的药物组合物和制备化合物(I)的方法。 还提供了式(I)的HCV抑制剂与利托那韦的生物可利用组合。